Jack Barkin
About
Jack Barkin is a scholar working on Urology, Pulmonary and Respiratory Medicine and Rheumatology.
According to data from OpenAlex, Jack Barkin has authored 92 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Urology, 43 papers in Pulmonary and Respiratory Medicine and 27 papers in Rheumatology. Recurrent topics in Jack Barkin's work include Urinary Bladder and Prostate Research (57 papers), Prostate Cancer Diagnosis and Treatment (39 papers) and Pelvic floor disorders treatments (27 papers). Jack Barkin is often cited by papers focused on Urinary Bladder and Prostate Research (57 papers), Prostate Cancer Diagnosis and Treatment (39 papers) and Pelvic floor disorders treatments (27 papers). Jack Barkin collaborates with scholars based in Canada, United States and Italy. Jack Barkin's co-authors include Claus G. Roehrborn, Paul Siami, Betsy Morrill, Ronaldo Damião, Francesco Montorsi, Kim Major‐Walker, R. Paul Gagnier, Indrani Nandy, J. Curtis Nickel and Joseph L. Chin and has published in prestigious journals such as The Journal of Urology, European Urology and Urology.
In The Last Decade
Jack Barkin
90 papers receiving 3.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jack Barkin Canada | 34 | 2.8k | 2.0k | 1.7k | 868 | 545 | 92 | 3.9k | ||
| A. Descazeaud France | 26 | 2.7k 1.0× | 2.0k 1.0× | 1.5k 0.9× | 599 0.7× | 310 0.6× | 140 | 3.6k | ||
| Marc Gittelman United States | 27 | 1.9k 0.7× | 1.3k 0.6× | 1.1k 0.7× | 911 1.0× | 524 1.0× | 70 | 3.3k | ||
| Claude Schulman Belgium | 28 | 885 0.3× | 1.6k 0.8× | 439 0.3× | 1.1k 1.2× | 137 0.3× | 99 | 3.2k | ||
| Martin Marszalek Austria | 22 | 839 0.3× | 845 0.4× | 483 0.3× | 430 0.5× | 195 0.4× | 56 | 2.0k | ||
| M Kontturi Finland | 26 | 844 0.3× | 958 0.5× | 584 0.3× | 558 0.6× | 248 0.5× | 107 | 2.4k | ||
| Ahmad Shabsigh United States | 31 | 1.2k 0.4× | 954 0.5× | 217 0.1× | 653 0.8× | 121 0.2× | 84 | 3.7k | ||
| P. Rigatti Italy | 26 | 560 0.2× | 839 0.4× | 309 0.2× | 428 0.5× | 57 0.1× | 139 | 2.1k | ||
| Emilio Sacco Italy | 22 | 858 0.3× | 907 0.4× | 744 0.4× | 71 0.1× | 294 0.5× | 171 | 2.2k | ||
| K.P.J. Delaere Netherlands | 21 | 373 0.1× | 803 0.4× | 407 0.2× | 230 0.3× | 131 0.2× | 68 | 1.6k | ||
| Hayato Yamamoto Japan | 26 | 445 0.2× | 738 0.4× | 240 0.1× | 99 0.1× | 155 0.3× | 196 | 2.5k |
Countries citing papers authored by Jack Barkin
Since
Specialization
Citations
This map shows the geographic impact of Jack Barkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack Barkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack Barkin more than expected).
Fields of papers citing papers by Jack Barkin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jack Barkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack Barkin. The network helps show where Jack Barkin may publish in the future.
Co-authorship network of co-authors of Jack Barkin
This figure shows the co-authorship network connecting the top 25 collaborators of Jack Barkin. A scholar is included among the top collaborators of Jack Barkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jack Barkin. Jack Barkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jc, Lee, et al.. (2019). The My-T study: Patient satisfaction and preference comparing topical and nasal testosterone therapies. Canadian Urological Association Journal. 13(11). 384–389.
2.
Nickel, J. Curtis, et al.. (2018). Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Canadian Urological Association Journal. 12(10). 303–312.
3.
Barkin, Jack, et al.. (2015). Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.. PubMed. 22(4). 7914–23.
4.
Miner, Martin, Matt T. Rosenberg, & Jack Barkin. (2014). Erectile dysfunction in primary care: a focus on cardiometabolic risk evaluation and stratification for future cardiovascular events.. PubMed. 21 Suppl 2. 25–38.
5.
Elterman, Dean, Bilal Chughtai, Steven A. Kaplan, & Jack Barkin. (2013). Tolterodine for the treatment of urge urinary incontinence. Expert Opinion on Pharmacotherapy. 14(14). 1987–1991.
6.
Herschorn, Sender, Jack Barkin, David Castro‐Díaz, et al.. (2013). A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder. Urology. 82(2). 313–320.
7.
Barkin, Jack. (2011). HIFU: Definitely ready for prime time. Canadian Urological Association Journal. 5(6). 422–423.
8.
Roehrborn, Claus G., Jack Barkin, Paul Siami, et al.. (2011). Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4‐year results from the randomized, double‐blind Combination of Avodart and Tamsulosin (CombAT) trial. British Journal of Urology. 107(6). 946–954.
9.
Roehrborn, Claus G., Jack Barkin, Paul Siami, et al.. (2010). 1782 CLINICAL OUTCOMES BY BASELINE PROSTATE VOLUME IN MEN WITH BENIGN PROSTATIC HYPERPLASIA: 4 YEAR RESULTS FROM THE COMBINATION OF AVODART AND TAMSULOSIN (COMBAT) TRIAL. The Journal of Urology. 183(4S).
10.
Herschorn, Sender, Lynn Stothers, Kevin Carlson, et al.. (2010). Tolerability of 5 mg Solifenacin Once Daily Versus 5 mg Oxybutynin Immediate Release 3 Times Daily: Results of the VECTOR Trial. The Journal of Urology. 183(5). 1892–1898.
11.
Morales, Álvaro, et al.. (2009). Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosteronevs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. The Aging Male. 12(4). 104–112.
12.
Roehrborn, Claus G., Paul Siami, Jack Barkin, Ronaldo Damião, & Francesco Montorsi. (2007). MP-20.28: Dutasteride provides greater improvement in symptoms and Qmax than tamsulosin in men with moderate-to-severe symptoms of BPH and prostate enlargement: Two-year results from the Combination of Avodart® and Tamsulosin (CombAT) study. Urology. 70(3). 160–160.
13.
Roehrborn, Claus G., et al.. (2007). POD-06.02: The effects of dutasteride, tamsulosin, and combination therapy on lower urinary tract symptoms and Qmax in men with BPH and prostatic enlargement: Two-year results from the Combination of Avodart® and Tamsulosin (CombAT) study. Urology. 70(3). 19–19.
14.
Siami, Paul, et al.. (2007). MP-20.16: Safety and tolerability of dutasteride, tamsulosin and a combination of dutasteride and tamsulosin: Two-year results from the Combination of Avodart® and Tamsulosin (CombAT) study. Urology. 70(3). 155–155.
15.
Sarosdy, Michael F., Jack Barkin, Julia A. Bridge, et al.. (2006). Use of a Multitarget Fluorescence In Situ Hybridization Assay to Diagnose Bladder Cancer in Patients With Hematuria. The Journal of Urology. 176(1). 44–47.
16.
Hatzichristou, Dimitrios, Philip J. Aliotta, Stephen M. Auerbach, et al.. (2005). Erectile response to vardenafil in men with a history of nonresponse to sildenafil: A time-from-dosing descriptive analysis. Clinical Therapeutics. 27(9). 1452–1461.
17.
Nickel, J. Curtis, Joe Downey, Janet Clark, et al.. (2003). Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology. 62(4). 614–617.
18.
Parsons, C. Lowell, John B. Forrest, J. Curtis Nickel, et al.. (2002). Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology. 59(3). 329–333.
19.
Klotz, Laurence, S. Larry Goldenberg, Michael A.S. Jewett, et al.. (1999). CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Urology. 53(4). 757–763.
20.
Elhilali, Mostafa, Ernest W. Ramsey, Jack Barkin, et al.. (1996). A multicenter, randomized, double-blind, placebocontrolled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology. 47(3). 335–342.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by A. Descazeaud Breakdown of academic impact, for papers by Marc Gittelman Breakdown of academic impact, for papers by Claude Schulman Breakdown of academic impact, for papers by Martin Marszalek Breakdown of academic impact, for papers by M Kontturi Breakdown of academic impact, for papers by Ahmad Shabsigh Breakdown of academic impact, for papers by P. Rigatti Breakdown of academic impact, for papers by Emilio Sacco Breakdown of academic impact, for papers by K.P.J. Delaere Breakdown of academic impact, for papers by Hayato Yamamoto